Literature DB >> 26261516

Effects of rhBNP on myocardial fibrosis after myocardial infarction in rats.

Zhendong Su1, Guoqian Wei1, Li Wei1, Junyan Liu1, Xueqi Li1.   

Abstract

PURPOSE: We aimed to observe the effects and mechanism of rhBNP treatment on myocardial fibrosis (MF) after myocardial infarction (MI).
METHODS: SPF rats were separated into 3 groups: normal, MI (ligation of left coronary artery), and MI + rhBNP (recombinant human brain natriuretic peptide). Rats in MI + rhBNP group were given 30 μg/kg for 2 days before modeling and for 4 weeks after modeling. mRNA levels and the expression levels of TGF-β1 (transforming growth factor) and CTGF (connective tissue growth factor) in 3 groups were analyzed using the RT-qPCR and western blotting analysis, respectively. Furthermore, myocardial volume fraction (CVF) was analyzed using the Sirius Red F3B (SR) while the percentage of type I and III collagen in 3 groups were analyzed using the immunohistochemical staining.
RESULTS: Compared with the normal group, the levels of TGF-β1, CTGF, CVF, type I and III collagen were higher in MI group. However, mRNA levels of TGF-β1 and CTGF were significantly decreased in MI + rhBNP compared to MI groups. Expression of TGF-β1 was lower while that of CTGF was higher in MI + rhBNP group than that in MI group. Besides, CVF, and type I and III collagen were lower in MI + rhBNP group compared with MI group.
CONCLUSION: rhBNP could significantly decrease the TGF-β1 and CTGF levels in post-MI so as to inhibit the type I and III collagen deposition in MF of post-MI. rhBNP will be benefit for the improvement of MF.

Entities:  

Keywords:  Recombinant human brain natriuretic peptide (rhBNP); TGF-β1; connective tissue growth factor (CTGF); myocardial fibrosis; myocardial infarction

Mesh:

Substances:

Year:  2015        PMID: 26261516      PMCID: PMC4525850     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

Review 1.  The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.

Authors:  W D Strain
Journal:  Int J Clin Pract       Date:  2004-11       Impact factor: 2.503

2.  Connective tissue growth factor and cardiac fibrosis after myocardial infarction.

Authors:  Rachael G Dean; Leanne C Balding; Riccardo Candido; Wendy C Burns; Zemin Cao; Stephen M Twigg; Louise M Burrell
Journal:  J Histochem Cytochem       Date:  2005-06-13       Impact factor: 2.479

Review 3.  The role of natriuretic peptides in cardioprotection.

Authors:  Toshio Nishikimi; Nobuyo Maeda; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2005-11-10       Impact factor: 10.787

4.  Myocardial collagen turnover after surgical ventricular restoration in heart failure patients.

Authors:  Ellen A ten Brinke; Tomasz G Witkowski; Victoria Delgado; Patrick Klein; Margreet Klok; Nina A Marsan; Robert J Klautz; Ernst E van der Wall; Jeroen J Bax; Arnoud van der Laarse; Paul Steendijk
Journal:  Eur J Heart Fail       Date:  2011-08-16       Impact factor: 15.534

5.  Purification of RNA using TRIzol (TRI reagent).

Authors:  Donald C Rio; Manuel Ares; Gregory J Hannon; Timothy W Nilsen
Journal:  Cold Spring Harb Protoc       Date:  2010-06

6.  Extraction, chemical analysis of Angelica sinensis polysaccharides and antioxidant activity of the polysaccharides in ischemia-reperfusion rats.

Authors:  Song Zhang; Ben He; Junbo Ge; Huibin Li; Xiuying Luo; Hui Zhang; Yuhui Li; Changlin Zhai; Pingang Liu; Xin Liu; Xuetao Fei
Journal:  Int J Biol Macromol       Date:  2010-08-05       Impact factor: 6.953

7.  Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

Authors:  Alberto Palazzuoli; Donald S Silverberg; Francesca Iovine; Anna Calabrò; Maria S Campagna; Maddalena Gallotta; Ranuccio Nuti
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

Review 8.  B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target.

Authors:  Rebecca H Ritchie; Anke C Rosenkranz; David M Kaye
Journal:  Curr Mol Med       Date:  2009-09       Impact factor: 2.222

9.  Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction.

Authors:  Susana M Chuva de Sousa Lopes; Alie Feijen; Jeroen Korving; Olexander Korchynskyi; Jonas Larsson; Stefan Karlsson; Peter ten Dijke; Karen M Lyons; Roel Goldschmeding; Pieter Doevendans; Christine L Mummery
Journal:  Dev Dyn       Date:  2004-11       Impact factor: 3.780

10.  Factors associated with the overall survival of elderly patients with hepatocellular carcinoma.

Authors:  Hideki Fujii; Yoshito Itoh; Naoki Ohnishi; Masafumi Sakamoto; Tohru Ohkawara; Yoshihiko Sawa; Koichi Nishida; Yasuo Ohkawara; Kanji Yamaguchi; Masahito Minami; Takeshi Okanoue
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

View more
  2 in total

1.  miR-30a attenuates cardiac fibrosis in rats with myocardial infarction by inhibiting CTGF.

Authors:  Liwen Chen; Qian Ji; Hao Zhu; Yizhi Ren; Zhongguo Fan; Nailiang Tian
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

2.  The Expression of BNP, ET-1, and TGF-β1 in Myocardium of Rats with Ventricular Arrhythmias.

Authors:  Meihui Tian; Ying Xiao; Jiajia Xue; Yuan Zhang; Yuqing Jia; Xinyi Luo; Tianqi Wang; Baoli Zhu; Zhipeng Cao
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.